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Abstract
The spatial conformation of a molecule, in general, is closely connected to its interac‐
tion with the human body, meaning bioreceptors, metabolizing enzymes, transport‐
ing proteins, etc. This chapter provides useful information regarding the importance of
spatial conformation(s) of anticoagulant molecules in their pharmacological activity. It
is divided in several sections: firstly, a short introduction is made into the world of
stereochemistry, and the importance of this field to the pharmacotherapy is highlight‐
ed. Then, each anticoagulant class is treated regarding their spatial orientations and
their significance linked to the mechanism of action, anticoagulant activity, potency, etc.
Keywords: stereochemistry, biochemistry, spatial conformation, enantiomer
1. Introduction
The mechanism of action of anticoagulants is very complex, involving many biochemical
reactions. The coagulation cascade which is finally blocked and the formation of a clot is
stopped in a direct (e.g. direct Xa factor inhibitors) or indirect way (e.g. vitamin K antago‐
nists)  assume many reactions,  which involve the activation of  factors,  cofactors  and en‐
zymes. The coagulation cascade involves a series of protein conformation changes, which are
called “activations” and which are dependent one to each other leading to this cascade series
of reactions. Most of these reactions are calcium-dependent, and some of them are vitamin K-
dependent (also known as the anti-haemorrhagic vitamin). The coagulation cascade ends with
the formation of a fibrin clot, and it can be stopped by interruption by natural ways, such as
genetic disorders (e.g. haemophilia A, B or C) or by extrinsic ways, when administering
anticoagulants. As well known, when it comes about natural-occurring compounds, these
reactions  are  very  specific,  but  when  it  comes  about  external  synthetic  derivatives,  the
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receptors can be “tricked” in different ways. One cause could be the stereochemistry of these
compounds, which is also important for these specific interactions.
Stereochemistry can be named the chemistry of 3D compounds and shows the relationship
between a spatial orientation of a molecule and its physical and chemical properties. Very
often, when a drug molecule can adopt different spatial shapes and forms, its reactivity with
the biomolecules can change. Taking into consideration that from its introduction to the human
organism until its excretion, a drug will meet tens, hundreds or even more types of biomole‐
cules, its reactivity is translated into its pharmacological effects, but its toxicity is expected to
depend also on its spatial orientation.
The aim of this chapter is to highlight the importance of stereochemistry in anticoagulation
therapy, following each subclass of anticoagulants. For this purpose, we present basic notions
of stereochemistry with details about the importance of spatial conformations of drug
molecules related to the biochemistry of these drugs, and in the end of the chapter, we will
find out whether the 3D structure of anticoagulants should be thought of in an anticoagulation
treatment plan.
2. Basics of stereochemistry
Stereochemistry is defined as chemistry of spatial isomers. When one refers to stereoisomers,
generally they are divided into two categories: firstly, there are the enantiomers, which are given
by the asymmetry of a certain compound, and secondly, there are the diastereomers, which
include all other conformational isomers which are not enantiomers.
In living organisms, the isometry given by enantiomers, also called chirality, is very important.
As mentioned before, they are defined by asymmetry. The asymmetry of a molecule can come
in two ways:
• When a carbon atom has four different substituents; in this case, the carbon atom is
represented by a centre of asymmetry and is called asymmetrical carbon atom; in this case,
one can talk about planar chirality; there are other types of atoms, such as N or P, which can
confer asymmetry to a molecule, but these cases are rarer.
• Usually, in case of macromolecules, such as polypeptides, proteins, DNA, etc., the whole
molecule presents a conformational asymmetry; in this case, one can talk about intrinsic or
helicoidal chirality. We can say that even the human body, if it were regarded as one molecule,
has intrinsic chirality, on the inside and also on the outside, as we are not perfectly sym‐
metrical.
The enantiomers of a molecule are represented as the object and its self-mirror-image
(Figure 1), which are not superimposable.
Under physical and chemical aspects, the two enantiomers of a pair present the same physical
properties (same melting point, same boiling point, same density, etc.) and, unlike diaster‐
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eomers, have the same chemical properties in non-chiral environment. Their properties differ
only in chiral environment.
Figure 1. Pair of enantiomers—(S)-enantiomer in the left and (R)-enantiomer in the right—represented as object and its
self-mirror-image.
Another different property of enantiomers is their behaviour in polarized light. In one pair of
enantiomer, one enantiomer will rotate the plan of polarized light towards the left with a
certain angle, while the other one will rotate the plan of polarized light with the same angle
but in the other direction. The first enantiomer will be called levogyre and is noted (−) or l, and
the other one is called dextrogyre and is noted (+) or d. The equimolar mixture of the two
enantiomers is called racemic mixture, is noted with ± and does not affect the plan of polarized
light.
Another internationally accepted nomenclature of enantiomers is the Cahn-Ingold-Prelog
nomenclature. This uses the absolute configuration of the molecules, which involves the
position of the four groups surrounding the asymmetrical carbon atom. They are numbered
from the lightest atom directly bonded to the asymmetrical carbon to the heaviest. If the order
of reading is towards the right side (or clockwise), the enantiomer is called R (or rectus); if the
order of reading is towards the left side (or counterclockwise), the enantiomer is called S (or
sinister) (Figure 1). Conventional D or L nomenclature is used for amino acids and saccharides.
This should not be confused with the d or l nomenclature. For this reason, to indicate whether
an enantiomer is levogyre or dextrogyre, the (+) or (−) notation is preferred.
One molecule will always have a number of 2n−1 pairs of enantiomers, where n represents the
number of centres of asymmetry of the molecule. For example, the coumarinic anticoagulant
warfarin (see Figure 5) has one centre of asymmetry represented by one asymmetrical carbon
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atom; thus, the molecule will have two enantiomers or one pair of enantiomers. The optical
isomers of the molecule which are not enantiomers (one with each other) are called diaster‐
eomers. In case of a symmetrical molecule where one chiral centre compensates the effect of
another one, the enantiomers are practically identical, and they are called mesomers.
There are other types of stereoisomerism, where molecules can adopt different spatial
conformations. The conformational isomerism of saccharides is worth mentioning. For
example, D-glucose can adopt a chair or a boat conformation, a function of the display of the
carbon atoms in the hexa-atomic cycle in space. The helicoidal chirality of proteins and other
macromolecules should not be left behind.
2.1. Importance of chirality in human life
The reaction between a drug and its receptor is usually a specific reaction between the target
molecule and a protein which acts as receptor. As macromolecules, the protein receptors are
almost always chiral, so one can expect in case of chiral drugs to meet an enantioselective drug-
receptor interaction, which could lead to different effects translated in the pharmacological
activity of the molecule.
When it comes about chiral drugs, there can be five cases in which the two enantiomers of a
drug can react with the receptors of the human body, translated in their pharmacological or
toxicological activities [1]:
• The most common case is when the two enantiomers have the same pharmacological
activities. At first sight, the use of a single enantiomer would not be necessary. However,
there are many substances which have one enantiomer (eutomer) 5, 10 up to 60 times more
active than the other one (distomer). This is the case of adrenaline, omeprazole or coumarinic
anticoagulants. In case of omeprazole, it is long time since the eutomer, (S)-(−)-omeprazole,
has been introduced on the pharmaceutical market as the single enantiomer (Nexium®). The
case of coumarinic anticoagulants will be discussed in Section 4.
• There can be the case when only one of the enantiomer is pharmacologically active, while
the other one is inactive. In this case, a separation of the two enantiomers is not strictly
necessary. However, in some cases, when the two enantiomers have different metabolic
pathways, a chiral separation could prevent some drug-drug interactions.
• When the eutomer and the distomer have totally opposite pharmacodynamic effects, a chiral
separation would be necessary. However, in many cases, the racemic mixture is used in
therapy, preserving the effect of the most potent enantiomer.
• Another example is the well-known case of thalidomide, in which the eutomer is responsible
for the pharmacological activity, while the distomer is responsible for the adverse effects.
In this case, the separation of the two enantiomers is mandatory.
• There are cases when using the racemic mixture is more beneficial, compared to the use of
the single enantiomers.
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As it can be seen, there are some cases when the use of the single enantiomer in drug therapy
is mandatory. Moreover, even in other cases, this choice may have many benefits compared
to the classical use of the racemic mixture. For these reasons, some drugs which were previ‐
ously used as racemic mixtures have been “rediscovered” and have been reintroduced in
pharmaceutical formulations as their single enantiomer form. This phenomenon is called chiral
switch, and one of the most recent examples is represented by dexlansoprazole, the eutomer
of lansoprazole, commercialized under the name of Dexilant® [2].
All these above-mentioned indicate clearly that the spatial conformation of an active molecule
is very important for its pharmacological activity and, moreover, for its possible toxicological
effects to the human body.
3. Heparin and related compounds
Heparin is a natural linear polysaccharide, which belongs to the class of glycosaminoglycans,
formed of glucosamine units alternating with glucuronic acid and iduronic acid units, bearing
N-sulphate, O-sulphate and N-acetyl groups. It acts as an anticoagulant by binding to
antithrombin III and changing its conformation, leading to its activation. It is biosynthesized
by enzymatic cleavage of the macromolecular heparin, a proteoglycan. Its composition can be
very heterogeneous, depending on the type of tissue where it is extracted from and of the
species. A very similar polysaccharidic structure is represented by heparan sulphate.
A specific pentasaccharide sequence (Figure 2), formed of glucuronic and iduronic sulphated
units, has been identified as the active site of heparin for antithrombin III [3].
Figure 2. Sequence of the specific pentasaccharide in heparin, which runs as active site for antithrombin III (As, D-
glucosamine-N-sulphate; G, α-D-glucuronic acid; As*, D-glucosamine-N-6-disulphate; Is, α-D-iduronic acid).
The conformational studies of the pentasaccharide sequence of heparin realized by 1H-RMN
and mechanical calculations [4] have shown that this sequence is formed of a rigid trisaccharide
and a more flexible disaccharide. The rigid trisaccharide is based on a glucuronic acid unit,
and it is supposed to be responsible for the direct bonding to the active site of antithrombin
III, while the flexible disaccharide is based on an iduronic acid unit, it can take several
conformations due to the iduronic acid flexibility, which can show different ring conforma‐
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tions, and the “choice” of a certain conformation can decide the bonding to other sites of the
antithrombin III molecule. NMR and molecular modelling studies have shown that the
iduronate residue in the pentasaccharide sequence can adopt several conformations of the
pyranose ring. Results have shown that the most stable conformations in terms of lowest
calculated energies are two chair conformations—1C4 and 4C1—and a twisted conformation,
so-called skew-boat conformation, noted 2S0, and in the heparin polymer, the iduronate unit
is found as a mixture of these three conformations. Studies have shown these conformations
are interconvertible [4–6] (Figure 3).
Figure 3. Structures of heparin determined by NMR studies, shown with the iduronic acid unit in the chair 1C4 confor‐
mation (left) and in the skew-boat 2S0 conformation (right). Reproduced from Mulloy and Forster [6] with permission
of Oxford University Press.
We can notice that the spatial conformation is very important in case of heparin starting even
from its mechanism of action. Jin et al. [7] have elucidated the mechanism of interaction
between the heparin-active pentasaccharide and antithrombin III. The mechanistic study
revealed that the antithrombin molecule suffers several conformation rearrangements which
allow the pentasaccharide to enter the active site. More specific, the α-helix rearranges allowing
the formation of hydrogen bonds with the sulphate groups in the pentasaccharide; the α-sheet
is closing, while residues in the active loop are partially expulsed, and the D-helix is extended
by one-and-a-half turns (Figure 4).
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Figure 4. Comparison between free antithrombin III conformation (left) and antithrombin-pentasaccharide complex
conformation (right). α-Sheet is closed (magenta), D-helix is extended (blue), and residues in active loop are expulsed
(black and green dots). Reproduced from Jin et al. [7] with permission of National Academy of Sciences of the USA.
Thus, the active site loop is partially inserted into the α-sheet, until the antithrombin molecule
forms the complex with the pentasaccharide of the heparin polymer. Consequently, the
antithrombin-pentasaccharide complex formation and activation model could be extended to
the whole heparin polymer. Moreover, by elaborating this model, the authors [7] have
demonstrated the importance of conformation changes which take place in antithrombin
molecule. A valuable example is the case of natural mutations of antithrombin, which lead to
thromboembolic syndrome. Any replacement of any amino acid in the active site of the
antithrombin molecule will lead to its inactivity by incapacity of conformation change, because
of incomplete or lack of binding sites to the pentasaccharide.
In addition to the conformational change of antithrombin, Verli and Guimarães [8] have
described the conformational change of the pentasaccharide, when forming the complex with
antithrombin, thus leading to an induced fit mechanism of reaction. A change in the dihedral
angles between the glucosamine and iduronic acid unit and, respectively, between glucosa‐
mine and glucuronic acid unit, from 20 to 30° was observed, even if the pentasaccharide was
in skew-boat 2S0 conformation or in chair 1C4 conformation. This gives a new perspective to
the mechanism of interaction between heparin and antithrombin, where the conformational
flexibility is important on both sides, the ligand and the substrate. Taking a deeper view into
the induced fit mechanism of interaction between heparin and antithrombin, it is worth
mentioning that there is a need of 7 up to 30 hydrogen bonds for the complex to get formed.
This information is essential for the drug development and design for new anticoagulant
structures, heparin-related [8]. For example, the highly sulphated saccharidic polymer of
heparin was replaced by a highly sulphated lignin, to obtain a new anticoagulant potential
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drug [9], with reduced bleeding side effects compared to the low-molecular-weight heparin
derivative, enoxaparin.
As the activation of antithrombin was understood as an interaction between certain oligosac‐
charides and the substrate, thus understanding that not the entire polymer of heparin partic‐
ipates in the activation of the antithrombin, other similar pentasaccharides or other
oligosaccharides with potential anticoagulant activity have also been synthesized. In the same
time, heparin was fractionated to lower-molecular-weight polymers, which were not as
heterogeneous in composition as the original heparin.
The chirality (asymmetry) of heparin has also been used in chiral separations, where heparin
has been utilized as a chiral selector. For example, Jin and Stalcup [10] have used heparin as
chiral additive to the background electrolyte in capillary electrophoresis (CE), for the separa‐
tion of several antihistaminic chiral drugs, such as pheniramine, chlorpheniramine, bromphe‐
niramine, carbinoxamine and doxylamine. The mechanism of enantioseparation was proposed
as being a combination between inclusion complex formation and electrostatic interaction.
4. Coumarinic anticoagulants (vitamin K antagonists)
Unlike heparin and related derivatives, coumarinic anticoagulants have relatively small
molecules, and their anticoagulant mechanism of action is totally different. They act by
inhibiting the epoxide reductase which is involved in the recovery of vitamin K, after its
oxidation.
Warfarin is the most prescribed coumarinic anticoagulant in the USA and UK. Besides
warfarin, in other European countries, acenocoumarol and phenprocoumon are used as
vitamin K antagonists (Figure 5). In all three cases, they present chiral structures as they contain
a chiral carbon atom in their molecule, leading to the existence of two enantiomers in each
case.
Figure 5. Molecular structures of coumarinic anticoagulants: (a) warfarin, (b) acenocoumarol, and (c) phenprocoumon;
chiral centre is indicated with asterisk (C*).
In all three cases, there is a difference in the anticoagulant activity between the two enantiomers
of the substance. In case of warfarin and phenprocoumon, their (S)-(−)-enantiomers are two
up to five times more active than their optical isomers, (R)-(+)-phenprocoumon, and (R)-(+)-
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warfarin, respectively. In case of acenocoumarol, the (R)-(+)-antipode is around five times more
active than the (S)-(−)-enantiomer [11].
It is worth mentioning that the difference of only one nitro group between warfarin and
acenocoumarol structures leads to the reversal of potency of anticoagulant activity between
the two enantiomers; in consequence, (R)-(+)-warfarin and (S)-(−)-acenocoumarol are the more
potent ones.
This difference of anticoagulant activity between the enantiomers of coumarinic anticoagu‐
lants comes from two directions. Firstly, there are the genetic determinants, and secondly, the
different metabolic pathways can explain these differences.
To understand the two types of differences, one should understand the mechanism of action
of these anticoagulants. Briefly, they act by interfering in vitamin K-dependent reactions in the
organism [11]. Vitamin K, also known as coagulation vitamin or anti-haemorrhagic vitamin,
is required for the liver synthesis of some coagulation factors (II, VII, IX and X), protein C and
protein S. On the one hand, the above-mentioned molecules become active in γ-carboxylation
reaction vitamin K-dependent. Inactive proteins cannot pass through the coagulation cascade.
On the other hand, during these reactions, vitamin K suffers an oxidation to a 2,3-epoxide form,
which is inactive. The vitamin K 2,3-epoxide reductase (VKOR) is the enzyme which brings
vitamin K to its initial active form.
The coumarinic anticoagulants act by inhibiting the 2,3-epoxide reductase. Consequently,
vitamin K remains inactive, and so factors II, VII, IX and X remain inactive, and the coagulation
cascade is stopped.
Several studies [12–15] reveal that the main genetic polymorphisms responsible for the inter-
patient variability are for the VKOR enzyme, under its different VKORC1 haplotypes and the
cytochrome P450 2C9 isoenzyme (CYP2C9), involved in the metabolism of these coumarinic
anticoagulants. However, a more recent study [16] has proven the significant relationship
between VKORC1 genotypes and differences in pharmacodynamics of warfarin enantiomers.
The authors have shown that patients with TT genotype of VKORC1 are more sensitive to (S)-
warfarin and relatively more sensitive to (R)-warfarin. They have proven a clear anticoagulant
contribution of (R)-(+)-warfarin to the racemic mixture, even if the (S)-warfarin is the more
potent one. However, when administering the racemic in polytherapy, drug-drug interactions
may also occur because of (R)-warfarin; likewise, when administering an inhibitor of (R)-
warfarin, such as cimetidine, an increase in the anticoagulant effect is likely to appear. As these
interactions do not appear in all populations, it is likely to notice a relationship between (R)-
warfarin contribution to drug-drug interactions and the VKORC1 genotype [16].
The genotypes of the CYP2C9 isoenzyme are closely related to the anticoagulant activity of
these three molecules and their enantiomers. As this isoenzyme of CYP450 is the main route
of metabolism for all three drugs, there is a very close relationship between the pharmacoge‐
netics, pharmacokinetics and in the end pharmacodynamics of the molecule. Thijssen and
Ritzen [17] have proven the influence of CYP2C9 polymorphism on the different pharmaco‐
kinetics of the two enantiomers of acenocoumarol. The study results revealed that the plasma
concentrations of (S)-acenocoumarol at 7 hours after administration of racemic were higher
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for patients who presented the CYP2C9*2 or CYP2C9*3 alleles, compared to the control group
of CYP2C9*1/*1. In contrast, for (R)-acenocoumarol, it was not observed any significant
influence of the CYP2C9 polymorphism over its plasma concentration, when determined at 7
hours or at 24 hours after administration. For (S)-acenocoumarol, the plasma concentration at
24 hours was not detectable (see Table 1). These results show the importance of optical
conformation of a drug in vivo. In addition to all these data, in some cases, the presence of
other CYP2C9 alleles, such as *4, *5 or *6, should be taken in consideration [17]. In case of
warfarin and phenprocoumon, there is not such a distinct difference of clearance between the
two enantiomers, as can be seen in Figure 6.
Genotype (S)-acenocoumarol (ng/mL) (R)-acenocoumarol (ng/mL)
4 hours after
intake
7 hours after
intake
4 hours after
intake
7 hours after
intake
24 hours after
intake
*1/*1 (n = 9) 34.9 ± 18.1 5.1 ± 4.2 219 ± 48 146 ± 21 34.5 ± 5.3
*1/*2 (n = 7) 26.3 ± 12.5 9.9 ± 4.9 199 ± 40 135 ± 31 31.7 ± 5.9
*1/*3 (n = 6) 47.7 ± 18.7 14.6 ± 6.6 226 ± 31 151 ± 35 30.7 ± 16.9
*2/*3 (n = 3) 33.2 ± 8.0 16.6 ± 5.0 163 ± 27 136 ± 36 33.9 ± 0.6
*2/*2 (n = 1) 59.6 25.8 180 167 ND
ND, not determined; n, number of patients. Reproduced from Thijssen and Ritzen [17] with permission of John Wiley
and Sons, Inc.
Table 1. Plasma (R)- and (S)-acenocoumarol concentrations after oral intake of 8 mg racemic acenocoumarol: effect of
CYP2C9 polymorphism.
Figure 6. Intrinsic clearances of (a) (S)-acenocoumarol and (R)-acenocoumarol, (b) (S)-warfarin and (R)-warfarin and
(c) (S)-phenprocoumon and (R)-phenprocoumon, as calculated from Thijssen et al. [18, 19] and Ufer et al. [20].
As could be seen, the genetic polymorphism leads to a difference in pharmacokinetics of the
two enantiomers. In case of acenocoumarol, as it can be seen in Table 1, the half-life of (S)-
enantiomer is much shorter than of the (R)-enantiomer. In case of CYP2C9*1/*3, the half-life
of (S)-acenocoumarol may be even doubled, up to 4 hours, which may lead to an increase in
anticoagulant activity. However, even if (S)-acenocoumarol is one of the most potent
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anticoagulants in the 4-hydroxycoumarin class [18], its half-life seems to be too short for the
(S)-acenocoumarol to interfere in the vitamin K-dependent reactions and to stop the coagu‐
lation cascade. Consequently, we can say that generally the effect of the racemic mixture is
given by the (R)-acenocoumarol.
Another difference of pharmacokinetics between the two acenocoumarol enantiomers is given
by the isoenzymes responsible for their metabolism. While CYP2C9 [18] seems to be the main
enzyme to transform (S)-acenocoumarol to its 6- and 7-hydroxy-metabolites, in case of (R)-
acenocoumarol, there are several enzymes involved in this process, which can explain the
difference in their resulting in vivo half-life. (R)-acenocoumarol is 7-hydroxylated by CYP2C9,
but the 6-hydroxylation is mediated, partially by other CYP450 isoenzymes, such as CYP1A2
and CYP2C19. For these enzymes, other drug-drug interactions in polytherapy cases should
be predicted.
Phenprocoumon [12] seems to be less affected by CYP2C9, but its metabolism is realized
mainly by CYP3A4. Moreover, a significant quantity of this anticoagulant is eliminated under
untransformed form, while acenocoumarol and warfarin are almost totally metabolized
through hydroxylation. CYP4F2 and CYP2C18 have also been mentioned to participate in the
metabolism of coumarinic anticoagulants. Genetic polymorphism should be taken in consid‐
eration in this case, too. At the same time, different genetic variants of enzymes involved in
the chain of reactions on which the anticoagulant mechanism of these molecules is based
should be considered. For example, the different genotypes of epoxide-hydrolase (EPHX1) and
γ-glutamyl carboxylase (GGCX) can lead to different anticoagulant potencies [20–22].
Taking all these in consideration, it remains one question: is it worth to introduce the single
enantiomer use in therapy for these drugs? The answer is that in all cases, it should at least be
reflected about. The different routes of metabolism for the two pair-enantiomers, influenced
partially by pharmacogenetic factors as seen, give them not only different half-lives but also
different anticoagulant potencies. In addition to these, one should consider that in most cases,
these drugs come in polytherapy, exposing the patient to many drug-drug interactions. When
eliminating one of the two enantiomers, at least some of these metabolic pathways which lead
to drug-drug interactions can be eliminated. In this case, also food-drug interactions should
be considered, which can be partially eliminated, and by reducing the dose, the toxicity and
probably some of the adverse effects should decrease. So, as in other drug cases (e.g. omepra‐
zole and lansoprazole), a chiral switch may be considered for these coumarinic anticoagulants.
However, in case of acenocoumarol, even if the most anticoagulant active enantiomer seems
to be (S)-acenocoumarol, its short half-life makes it almost unusable, while the other enan‐
tiomer, (R)-acenocoumarol, which could be kept, presents many metabolic pathways which
anyways could not be avoided. In this case, other factors, such as economic elements, may be
considered, when having a chiral separation or chiral synthesis for the single enantiomer use.
There have been numerous chiral separation methods developed for the separation of these
three chiral drugs. These separations can be realized by high-performance liquid chromatog‐
raphy (HPLC), coupled with UV [23, 24] or mass spectrometer (MS) [25] detectors or by
capillary electrophoresis (CE) [26, 27]. However, in case of drug control analysis or chiral purity
analysis, there is not necessarily the need to effectively separate the two enantiomers but to
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know the enantiomeric ratio. For this purpose, p-tert-butylcalix[6]arene derivative has been
used as chiral selector for the chiral enantiorecognition of warfarin [28] in a UV-spectral study
coupled with the multivariate analysis of the spectral data. The results showed a good capacity
of enantiorecognition of the achiral molecule of calixarene towards the enantiomers of
warfarin, being able to determine the ratio of one enantiomer when this was in a proportion
of up to 5 % in the mixture. The impact of this study relies not only in the determination of the
enantiomeric ratio but in the fact that with the aid of multivariate analysis, which can interpret
seemingly messy and complicated data, the different behaviour of enantiomers can be
discovered even in achiral media, as achiral structures were used as chiral selectors.
5. Direct Xa factor and thrombin inhibitors
As this type of anticoagulants represents recently discovered molecules, their chirality has
been already explored in the preclinical phase studies, as regulators in the field (Food and
Drug Administration) demand it. To highlight once again the importance of chirality in
medical and pharmacological field, it is worth mentioning that among these substances, all
which are chiral, are used under their single enantiomer form (Figure 7).
Figure 7. Molecular structures of some direct Xa factor inhibitors: (a) rivaroxaban and (b) R1663, with indication of
chiral centre(s).
For example, the (S)-enantiomer of rivaroxaban is used in therapy, as it has a 10,000 times
higher affinity towards the active site of Xa factor compared to its pair enantiomer or its
diastereomers [29]. In contrast, the (R,R)-enantiomer of otamixaban is preferred as anticoagu‐
lant agent [30] as it fits better into the active site of Xa factor. In a similar way, the (R,R)-
enantiomer of a novel molecule, (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic
acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide},
named R1663, has already passed phase 1 clinical study for its introduction on the drug market
[31]. Edoxaban is another inhibitor of Xa factor used as the single enantiomer in therapy, while
it has three asymmetrical carbon atoms in its molecule.
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All these differences in spatial conformation actually exhibit a higher anticoagulant potency
or activity by a better interaction with the active site of the target substrate. The interaction
with the Xa factor must be seen like a “hand-glove” acceptance, where only one “hand” is most
suitable for the “glove”.
In a similar way, in case of chiral molecules used in therapy as thrombin inhibitors, one should
expect to see a difference in affinity towards the substrate, with a higher anticoagulant activity
of one enantiomer compared to the other one. Thus, the thrombin inhibitor argatroban
(Figure 8) is used in its single enantiomer form as (R,R)-enantiomer [32].
Figure 8. Molecular chiral structure of argatroban, with indication of all chiral centres (C*).
6. Proteic anticoagulants
Proteins, by their nature of macromolecules, are very dependent on their spatial conformation.
All natural proteins and polypeptides are formed of natural L-amino acids. The spatial
conformation of proteins is crucial for their activity as enzymes, drug receptors, etc.
Thrombin and antithrombin, as it could be seen previously, are two proteins involved in the
cascade of coagulation. There are several polypeptidic and proteic anticoagulants used in
therapy, which generally target these two molecules. It is worth mentioning the first intro‐
duction in therapy, in 2009, of recombinant human antithrombin-α obtained from transgenic
goats’ milk [33].
Another protein that has given very good results as anticoagulant in deep vein thrombosis is
batroxobin, a toxin extracted from Bothrops atrox and Bothrops moojeni venom [34]. Results
showed successful limb salvage for all patients taken in study after they were administered
batroxobin, due to anticoagulant and fibrinolytic mechanism of this molecule.
Hirudin is an antithrombin-like protein which possesses anticoagulant effects. It is a smaller
proteic molecule which binds to thrombin into its active site. Mengwasser et al. [35] have
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studied the hirudin-thrombin complex, in terms of stability, affinity one to each other and
conformation. Results showed a higher affinity of hirudin towards the fast (F) allosteric form
of thrombin, compared to the slow (S) form. There are common residues responsible for both
complex formations, but there are seven residues which are responsible for the more than 10
times higher affinity of hirudin towards the F form of thrombin. The residues Asp221 and
Asp222 do not interact directly with hirudin, the effect being probably a stabilization of the S
form by Na+ binding. The same effect could be for Gly-193. The other four residues—Lys36,
Leu65, Thr74 and Arg75—do interact directly with hirudin. The preference towards the F form
stays probably due to the different spatial orientation of these residues, leading to a better
“match” with hirudin in the F form (Figure 9).
Figure 9. Model of binding of hirudin (marine sticks) to the F (red) and S (green) forms of thrombin. The higher affinity
of hirudin towards F thrombin is indicated through the seven residues. The important residue Lys224, which makes an
important contribution to hirudin binding, is spotted in yellow. Reproduced from Mengwasser et al. [35] with permis‐
sion of the American Society for Biochemistry and Molecular Biology.
7. Concluding remarks
Taking all the above-mentioned in consideration, one can say that stereochemistry and the
spatial conformations play a key role in the life of a drug molecule, in general, and of an
anticoagulant, in special, in terms of pharmacogenetics, pharmacokinetics, pharmacotoxicol‐
ogy and/or pharmacodynamics. When talking about macromolecules, we cannot separate
them from their spatial conformation, which is an essential factor which influences their
activity. In case of small molecules, the existence of one or more pairs of enantiomers gives
them the possibility to act differently with the chiral receptors of the organism, with possible
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different effects to be observed. As already seen, these reactions depend also on the flexibility
of both the target molecule and the receptor macromolecule, but they usually take place
following a “hand-glove” model. Stereochemistry of anticoagulants is important in all aspects
and should be considered before establishing a treatment plan.
Acknowledgements
The authors are grateful for the financial support from the Romanian National Authority for
Scientific Research UEFISCDI for project no. PN-II-RU-TE-2014-4-0460.
Author details
Ioana-Daria Tiuca
Address all correspondence to: tiuca.daria@umfcluj.ro
“Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
References
[1] Zhang J, Lin G. Chiral drugs and associated asymmetric synthesis. In: Huang Z, editor.
Drug Discovery Research: New Frontiers in the Post-Genomic Era. San Diego: Wiley
Interscience; 2007. p. 230–78.
[2] Gellad WF, Choi P, Mizah M, Good CB, Kesselheim AS. Assessing the chiral switch:
Approval and use of single-enantiomer drugs, 2001 to 2011. Am J Manag Care.
2014;20(3):90–7.
[3] Casu B. Heparin structure. Haemostasis. 1990;20(suppl 1):62–73. DOI:
10.1159/000216162
[4] Ragazzi M, Ferro D, Perly B, Sinay P, Petitou M, Choay J. Conformation of the penta‐
saccharide corresponding the binding site of heparin for antithrombin III. Carbohydr
Res. 1990;195(2):169–85. DOI:10.1016/0008-6215(90)84165-Q
[5] Mulloy B, Forster MJ, Jones C, Davies DB. N.m.r. and molecular-modelling studies of
the solution conformation of heparin. Biochem J. 1993;293(3):849–58. DOI: 10.1042/
bj2930849
[6] Mulloy B, Forster MJ. Conformation and dynamics of heparin and heparan sulfate.
Glycobiology. 2000;10(11):1147–56. DOI: 10.1093/glycob/10.11.1147
Biochemistry and Stereochemistry of Anticoagulants
http://dx.doi.org/10.5772/64417
15
[7] Jin L, Abrahams JP, Skinner R, Petitou M, Pike RM, Carrell RW. The anticoagulant
activation of antithrombin by heparin. Proc Natl Acad Sci USA. 1997;94(26):14683–8.
[8] Verli H, Guimarães JA. Insights into the induced fit mechanism in antithrombin -
heparin interaction using molecular dynamics simulations. J Mol Graph Model.
2005;24(3):203–12. DOI: 10.1016/j.jmgm.2005.07.002
[9] Mehta AY, Mohammed BM, Martin EJ, Brophy DF, Gailani D, Desai UR. Allosterism-
based simultaneous, dual anticoagulant and antiplatelet action: Allosteric inhibitor
targeting the glycoprotein Ib ?-binding and heparin-binding site of thrombin. J Thromb
Haemost. 2016; 14(4):828–38. DOI: 10.1111/jth.13254
[10] Jin Y, Stalcup AM. Application of heparin to chiral separations of antihistamines by
capillary electrophoresis. Electrophoresis. 2000;19(12):2119–23. DOI: 10.1002/elps.
1150191213
[11] Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College
of Cardiology foundation guide to warfarin therapy. J Am Coll Cardiol. 2003;41(9):
1633–52. DOI: 10.1016/S0735-1097(03)00416-9.
[12] Cadamuro J, Dieplinger B, Felder T, Kedenko I, Mueller T, Haltmayer M et al. Genetic
determinants of acenocoumarol and phenprocoumon maintenance dose requirements.
Eur J Clin Pharmacol. 2010;66(3):253–60. DOI: 10.1007/s00228-009-0768-7.
[13] Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A et al. Genetic
determinants of response to warfarin during initial anticoagulation. N Engl J Med.
2008;358(10):999–1008. DOI: 10.1056/NEJMoa0708078
[14] Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, Barry P et al. The impact of
CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon
warfarin dose requirements: Proposal for a new dosing regimen Blood. 2005;106(7):
2329–33. DOI: 10.1182/blood-2005-03-1108.
[15] Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral
anticoagulants. Pharmacogenomics. 2010;11(4):493–6. DOI: 10.2217/pgs.10.31.
[16] Maddison J, Somogyi AA, Jensen BP, James HM, Gentgall M, Rolan PE. The pharma‐
cokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered
separately and together: Relationship to VKORC1 genotype. Br J Clin Pharmacol.
2013;75(1):208–16. DOI: 10.1111/j.1365-2125.2012.04335.x.
[17] Thijssen HHW, Ritzen B. Acenocoumarol pharmacokinetics in relation to cytochrome
P450 2C9 genotype. Clin Pharmacol. Ther 2003;74(1):61–8. DOI: 10.1016/
S0009-9236(03)00088-2.
[18] Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of
racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug
Metab Dispos. 2000;28(11):1284–90.
Anticoagulation Therapy16
[19] Hermans JJ, Thijssen HH. Human liver microsomal metabolism of the enantiomers of
warfarin and acenocoumarol: P450 isozyme diversity determines the differences in
their pharmacokinetics. Br J Pharmacol. 1993;110(1):482–90. DOI: 10.1111/j.
1476-5381.1993.tb13836.x.
[20] Ufer M, Svensson JO, Krausz KW, Gelboin H V., Rane A, Tybring G. Identification of
cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxyla‐
tion in vitro. Eur J Clin Pharmacol. 2004;60(3):173–82. DOI: 10.1007/s00228-004-0740-5.
[21] Pautas E, Moreau C, Gouin-Thibault I, Golmard JL, Mahe I, Legendre C et al. Genetic
factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin
response in very elderly, frail inpatients. Clin Pharmacol Ther. 2010;87(1):57–64. DOI:
10.1038/clpt.2009.178.
[22] Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RHN, Hofman
A et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum
Mol Genet. 2009;18(19):3758–68. DOI: 10.1093/hmg/ddp309.
[23] Ding GS, Huang XJ, Liu Y, Wang JD. Chiral separation of racemates of drugs and amino
acid derivatives by high-performance liquid chromatography on a norvancomycin-
bonded chiral stationary phase. Chromatographia. 2004;(7):443–9. DOI: 10.1365/
s10337-004-190-3.
[24] Valliappan K, Vaithiyanathan SJ, Palanivel V. Direct chiral HPLC method for the
simultaneous determination of warfarin enantiomers and its impurities in raw material
and pharmaceutical formulation: Application of chemometric protocol. Chromatogra‐
phia. 2013;76(5–6):287–92. DOI: 10.1007/s10337-012-2373-7.
[25] Jensen BP, Chin PKL, Begg EJ. Quantification of total and free concentrations of R- and
S-warfarin in human plasma by ultrafiltration and LC-MS/MS. Anal Bioanal Chem.
2011;401(7):2187–93. DOI: 10.1007/s00216-011-5303-x
[26] Chankvetadze B, Burjanadze N, Crommen J, Blaschke G. Enantioseparation of warfarin
by capillary electrophoresis with UV and LIF detection using single and dual cyclo‐
dextrin type chiral selectors. Chromatographia. 2001;53(suppl1):296–301. DOI: 10.1007/
BF02490345
[27] Nowak P, Garnysz M, Mitoraj MP, Sagan F, Wo?niakiewicz M, Ko?cielniak P. Analyt‐
ical aspects of achiral and cyclodextrin-mediated capillary electrophoresis of warfarin
and its two main derivatives assisted by theoretical modeling. J Chromatogr A.
2015;1377:106–13. DOI: 10.1016/j.chroma.2014.12.030
[28] Bodoki E, Tiuca I, Iacob BC, Hosu O, Oprean R. Determination of the enantiomeric ratio
of warfarin in tablets by multivariate calibration and modeling of spectroscopic data.
Farmacia. 2012;60(3):386–93.
[29] Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer K-H et al.
Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomor‐
pholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide
Biochemistry and Stereochemistry of Anticoagulants
http://dx.doi.org/10.5772/64417
17
(BAY59-7939): An oral, direct factor Xa inhibitor. J Med Chem. 2005;48(19):5900–8. DOI:
18 10.1021/jm050101d.
[30] Guertin KR, Choi Y-M. The discovery of the Factor Xa inhibitor otamixaban: From lead
identification to clinical development. Curr Med Chem. 2007;14(23):2471–81. DOI:
10.2174/092986707782023659.
[31] Anselm L, Banner DW, Benz J, Groebke Zbinden K, Himber J, Hilpert H et al. Discovery
of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)- pyrrolidine-3,4-dicarboxylic acid
3-[(5-chloro-pyridin-2-yl)-amide] 4-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-
amide} as a clinical candidate. Bioorganic Med Chem Lett. 2010;20(17):5313–9. DOI:
10.1016/j.bmcl.2010.06.126.
[32] Ferraboschi P, Mieri M De, Grisenti P, Lotz M, Nettekoven U. Diastereoselective
synthesis of an argatroban intermediate, ethyl (2R,4R)-4-methylpipecolate, by means
of a Mandyphos/rhodium complex-catalyzed hydrogenation. Tetrahedron Asymme‐
try. 2011;22(16–17):1626–31. DOI: 10.1016/j.tetasy.2011.09.009
[33] Kling J. First US approval for a transgenic animal drug. Nat Biotechnol. 2009;27(4):302–
4. DOI: 10.1038/nbt0409-302
[34] Zhang L, Lu SH, Li L, Tao YG, Wan YL, Senga H et al. Batroxobin mobilizes circulating
endothelial progenitor cells in patients with deep vein thrombosis. Clin Appl Thromb
Hemost. 2011;17(1):75–9. DOI: 10.1177/1076029609347903.
[35] Mengwasser KE, Bush LA, Shih P, Cantwell AM, Di Cera E. Hirudin binding reveals
key determinants of thrombin allostery. J Biol Chem. 2005;280(29):26997–7003. DOI:
10.1074/jbc.M502678200
Anticoagulation Therapy18
